Skip to main content
Premium Trial:

Request an Annual Quote

Mark Chee, Karoly Nikolich, David Lockhart, Mostafa Ronaghi, Jeffrey Trent, Tracy Warren, Edward Erickson

Premium
Febit has formed a scientific advisory board. The board will be chaired by Mark Chee, CEO of Prognosys Biosciences, a collaborator of Febit. Chee is a co-founder of Illumina and a former Affymetrix scientist.
 
The other members are Karoly Nikolich, an entrepreneur and consultant, and the former executive director of the Neuroscience Institute of Stanford; David Lockhart, CSO of Amicus Therapeutics and a former Affymetrix employee; Mostafa Ronaghi, a senior research associate at the Stanford University Genome Technology Center and an inventor of pyrosequencing; and Jeffrey Trent, president and scientific director of the Translational Genomics Research Institute
 

 
Tracy Warren and Edward Erickson are joining the board of directors of BioNanomatrix, following the company’s recent $5.1 million Series A funding round (see Short Reads, in this issue). Warren is a general partner of Battelle Ventures, the lead investor in the round, and Erickson has “extensive experience” in the medical products industry, according to BioNanomatrix.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.